Cargando…
A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer
Cervical cancer, the second most common cause of cancer death in women worldwide, is significantly associated with infection of high-risk human papillomaviruses (HPVs), especially the most common genotype, HPV 16. To date, there is no established noninvasive therapy to treat cervical cancer. Methods...
Autores principales: | Jiang, Pengfei, Wang, Lude, Hou, Bailong, Zhu, Jinshun, Zhou, Meng, Jiang, Jie, Wang, Ledan, Chen, Shao, Zhu, Shanli, Chen, Jun, Zhang, Lifang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037027/ https://www.ncbi.nlm.nih.gov/pubmed/30026865 http://dx.doi.org/10.7150/thno.24607 |
Ejemplares similares
-
Generation of affibody molecules specific for HPV16 E7 recognition
por: Xue, Xiangyang, et al.
Publicado: (2016) -
Novel Affibody Molecules Targeting the HPV16 E6 Oncoprotein Inhibited the Proliferation of Cervical Cancer Cells
por: Zhu, Jinshun, et al.
Publicado: (2021) -
Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma
por: Zhu, Shanli, et al.
Publicado: (2020) -
Disruption of HPV16-E7 by CRISPR/Cas System Induces Apoptosis and Growth Inhibition in HPV16 Positive Human Cervical Cancer Cells
por: Hu, Zheng, et al.
Publicado: (2014) -
Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection
por: Gradissimo, Ana, et al.
Publicado: (2021)